In the Pfizer Study submitted to the VRBPAC, regarding boosters, Pfizer eliminated 34/268, or 13%, of the immunogenicity part of the study, due to a diagnosis of C19 up to 28 days post booster. page 26 https://www.fda.gov/media/152161/download